.jpg)
JonesTrading Institutional Services LLC (“JonesTrading”), a recognized industry leader for equity research in Healthcare, Financial Services and Energy sectors, continues recruiting top industry talents with Justin Walsh PhD and Sean Kim PhD joining the JonesResearch Healthcare team.
The appointments signal JonesTrading’s commitment to expand Healthcare research coverage and continue to provide proprietary fundamental analysis with the recruitment of analysts with broad and deep scientific backgrounds. Today’s appointments are consistent with that approach, serving to further build the JonesTrading franchise.
Justin Walsh PhD will be covering biotechnology companies within the Healthcare sector. Before joining JonesTrading, Dr. Walsh was a Research Analyst at B. Riley Securities covering SMID cap biotechnology and healthcare companies with a primary focus on oncology. Earlier, he contributed to the coverage of a diverse set of biotechnology companies as an equity research associate at JMP Securities and Raymond James & Associates. He earned his Ph.D. in chemistry from Hunter College and the City University of New York Graduate Center, wherein he collaborated with Memorial Sloan Kettering Cancer Center to study next-generation cancer imaging approaches. He holds a BA in chemistry and mathematics from Rollins College.
Sean Kim PhD will be covering biotechnology companies within the Healthcare sector. Before joining JonesTrading, Dr. Kim was a Senior Research Associate at Mizuho Securities, covering large cap US pharmaceuticals and SMID cap biotechnology companies. Previously, he worked as a research scientist for a number of biotechnology companies including Gilead Sciences and Nektar Therapeutics, and served as a faculty member in the School of Pharmacy at the University of Pittsburgh. He earned his PhD in Bioengineering from the University of California, Berkeley and San Francisco, and a BA in Mathematics and Computer Science from the University of California, Berkeley. He also completed his MBA at Haas School of Business, University of California, Berkeley.
Soumit Roy, Director of Research, JonesResearch said: “We have been building our research team in the Healthcare, Financial Services and Energy sectors over the past several years. This growth in research is consistent with the overall expansion of JonesTrading’s brokerage and banking services. Drs. Walsh and Kim bring biotechnology, bioengineering, pharmaceutical and financial expertise – put together to simplify Biotech stock analysis for all investors.”
Justin Walsh, Vice President, JonesResearch said: “Biotechnology companies are driven by unparalleled innovations, constantly developing new technologies to fulfill unmet needs. Our analysis intends to cut through the noise and identify overall trends and specific growth opportunities to benefit JonesTrading’s clients as they navigate this continuously changing sector. JonesTrading’s research has a substantial footprint and I look forward to building the franchise further.”
Sean Kim, Vice President, JonesResearch said: “We are entering a new phase where AI and synthetic biology is getting more and more integrated into traditional drug development processes. Our goal is to stay at the leading edge and identify opportunities ahead of the curve. An accurate analysis on risks and growth potentials in this sector, given its exponential expansion, is critical to the decisions JonesTrading’s clients make each day.”
